SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Emerging Challenges in Primary Care 2018 Denver, CO
Activity/Course #:
: 10.20.18PC
Cost:
: Free
Release/Start Date:
: Oct 20 2018
Expiration Date:
: Oct 20 2018
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 7.5 hours
Credit(s):
: 7.5 AMA PRA Category I Credit(s)
7.5 AANP Contact hour(s)
Hardware/Software Requirements:
Saturday, October 20, 2018
Sheraton Denver Tech Center
7007 S Clinton Street
Greenwood Village, CO 80112
(303) 799-6200

Registration Fee
There is no registration fee for this activity.

Special Accommodations
NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking
Complimentary self-parking is available at the hotel.

Program Summary
Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning objectives

At the conclusion of this program, participants should be able to:

1. Identify the barriers between clinicians and patients to discussing and initiating earlier insulin therapy for diabetes management; Discuss currently available basal and ultrabasal insulins and their pharmacokinetic/ pharmacodynamic profiles Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk; Describe how best to initiate, utilize and intensify insulin therapy in patients with diabetes while incorporating treatment guidelines and unique patient needs; Integrate strategies to improve the patient experience with, and adherence to, insulin therapy.

2. Review the epidemiology of primary biliary cholangitis (PBC); Describe the pathophysiology of PBC; Recognize how to evaluate a patient for PBC; Discuss the treatment of PBC, including the treatment of extrahepatic manifestations.

3. Discuss the pathophysiology of Alpha-1 antitrypsin deficiency (AATD) and its impact on chronic obstructive pulmonary disease (COPD) risk; Interpret the clinical significance of laboratory test results for AATD; Discuss treatment options for AATD and latest GOLD guideline recommendations; Discuss strategies to enhance detection and treatment of AATD in clinical practice.


4. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes; Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients; Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk; Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them.

5. Describe the indications and evidence base for the clinical use of benzodiazepines; Describe the major negative consequences to benzodiazepine use; Outline an approach to patients with benzodiazepine-related problems.


6. Outline physiologic and neurophysiologic effects of cannabis; Outline the major negative consequences of cannabis use; Describe the available evidence-based medical uses of cannabinoids; Discuss an approach to the patient using cannabis medically or recreationally.

 

 

Agenda*

 7:30-8:00 
     
Continental Breakfast and Registration
 8:00-8:10 Welcome Remarks
Gregg Sherman, MD
8:10-9:40
 Getting Comfortable with Insulin: New Approaches to Getting Patients Safely to Target
Mark Stolar, MD
9:40-10:50
 Recognition and Management of Primary Biliary Cholangitis (PBC): A Chronic
Inflammatory Liver Disease
Kalyan Ram Bhamidimarri, MD, MPH
10:50-11:10
 Break
11:10-12:20
 Finding the Needle in a Haystack: Diagnosing and Managing Alpha-1 Antitrypsin
Deficiency in Patients with COPD
Robert A. Sandhaus, MD, PhD, FCCP
12:20-1:20
 Lunch
1:20-2:30
 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Robert L. Gillespie, MD, FACC, FASE, FASNC
2:30-3:40
 Benzodiazepines: Boon or Blunder?
Steven Wright, MD
 3:40-3:50 Break
 3:50-5:00 Breakin’ Good? Or Breakin’ Bad? The Cannabis Conundrum
Steven Wright, MD
 5:00-5:05 Closing Remarks
Gregg Sherman, MD

 *Agenda subject to change.

Faculty

Kalyan Ram Bhamidimarri, MD, MPH
Transplant Hepatologist, University of Miami
Medical Director of Small Bowel & Multi-visceral Transplantation
Miami Transplant Institute
Miami, FL

Robert L. Gillespie, MD, FACC, FASE, FASNC
Immediate Past Chairman of the Board, Association of Black Cardiologists
Director of Nuclear Imaging, Sharp Rees-Stealy Medical Group
San Diego, CA

Robert A. Sandhaus, MD, PhD, FCCP
Professor of Medicine
Director, Alpha-1 Program
National Jewish Health
Clinical Director, Alpha-1 Foundation
Executive VP and Medical Director, AlphaNet
Medical Director, AlphaNet Canada
Coral Gables, FL

Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Steven Wright, MD
Family Medicine
Addiction Medicine, Board Certified
Medical Pain Management
Lakewood, CO


Planning Committee

Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL


Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education

Plantation, FL

Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Cassandra A. McCullough, MBA

Chief Executive Officer
Association of Black Cardiologists
New York, NY

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.50 contact hours of continuing education (which includes pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported by educational funding provided by Amgen; and an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.; an educational grant from Grifols; an educational grant from Intercept Pharmaceuticals; an educational grant from Sanofi US; and an educational grant from Sanofi US and Regeneron Pharmaceuticals.